Regeneron Pharmaceuticals reports $4.29 billion revenue for quarter ended June 30, 2026, up 16.7%
Regeneron Pharmaceuticals reported revenue of $4.29 billion for the quarter ended June 30, 2026, an increase of 16.7% from the same quarter a year earlier ($3.68 billion).
For the same period it posted net income of $1.3 billion, down 6.8%, or $12.23 per diluted share (12.81 a year earlier).
That is a net margin of 30.2%.
On Sanad's AAOIFI Standard 21 screen, Regeneron Pharmaceuticals is currently questionable: interest-bearing debt is 2.7% of market capitalisation (limit 30%), and impure income is 4.4% of revenue (limit 5%).
Is Regeneron Pharmaceuticals halal?
See the full AAOIFI screening of Regeneron Pharmaceuticals
See the full AAOIFI screening of Regeneron Pharmaceuticals
Source: 10-Q filed with the U.S. Securities and Exchange Commission on July 30, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.